HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
KURA
Kura Oncology, Inc.
There isn't enough reported data to score KURA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
KURA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
KURA's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
KURA PE Valuation
KURA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
KURA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect KURA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over KURA on earnings, with more consistent year-over-year improvement.
KURA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.30 | -$0.83 |
| Q2 2026 | -$3.37 | -$1.12 |
| Q1 2026 | -$3.35 | -$1.26 |
| Q4 2025 | -$3.18 | -$1.16 |
| Q3 2025 | -$2.47 | -$0.11 |
| Q2 2025 | -$2.25 | -$0.02 |
| Q1 2025 | -$2.09 | +$0.08 |
| Q4 2024 | -$2.02 | +$0.06 |
KURA lost $3.30 per share over the past year, a bigger loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over KURA in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over KURA on profitability, with a higher operating margin.
KURA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $22.8M | +10% |
| Q2 2026 | $20.9M | +37% |
| Q1 2026 | $18.3M | +29% |
HIMS has the edge over KURA in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -327% | +59 points |
| Q2 2026 | -350% | +126 points |
| Q1 2026 | -432% | +27 points |
| Q4 2025 | -498% | N/A |
| Q3 2025 | -386% | N/A |
| Q2 2025 | -475% | N/A |
| Q1 2025 | -459% | N/A |
KURA's operating margin was −327% last quarter, up 59 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over KURA on cash generation, producing positive trailing cash flow while its opponent burns cash.
KURA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$54.9M | +$28.3M |
| Q2 2026 | -$63.2M | -$33M |
| Q1 2026 | -$86M | -$13.8M |
| Q4 2025 | $115M | -57% |
| Q3 2025 | -$83.2M | -$39.8M |
| Q2 2025 | -$30.2M | +$12.3M |
| Q1 2025 | -$72.2M | -$23.3M |
| Q4 2024 | $268.8M | +$303.1M |
KURA has burned cash in almost every quarter: −$89M over the past year, against $83M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over KURA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
KURA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +962K shares |
| 1 year | +2.5% | +2.2M shares |
| 3 years | +16% | +12.6M shares |
| 5 years | +35% | +23.5M shares |
| Available history | +98% | +44.5M shares |
KURA has 90M diluted shares, up 2.5% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
KURA Net Leverage
KURA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
KURA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.4 | Neutral |
| Stochastic | 15.0 | Oversold |
KURA's weekly RSI is 38 (neutral) and its Stochastic is 15 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
KURA PE vs Healthcare Sector
KURA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
KURA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.46 | 21% below |
| 20 week MA | $10.5 | 29% below |
| 50 week MA | $9.76 | 24% below |
| 100 week MA | $8.72 | 15% below |
| 200 week MA | $11.9 | 37% below |
KURA is in a downtrend: it's below all five of its weekly moving averages, and 37% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
KURA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.2 | $36.0 | +153% |
| 2021 | $36.0 | $16.1 | -55% |
| 2022 | $16.1 | $11.7 | -27% |
| 2023 | $11.7 | $14.4 | +23% |
| 2024 | $14.4 | $8.67 | -40% |
| 2025 | $8.67 | $10.6 | +23% |
| 2026 YTD | $10.6 | $7.43 | -30% |
KURA has the edge over HIMS on returns for 2026, with the stronger performance.